DNA RNA and Cells

27 Sep 2021 Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis; Confirms Ability to Harness the Small Intestinal Axis, SINTAX™, to Treat Systemic Inflammatory Disease
27 Sep 2021 Takeda Receives Approval to Manufacture and Market Alofisel®▼ (darvadstrocel) in Japan for Treatment of Complex Perianal Fistulas in Patients with Non-active or Mildly Active Luminal Crohn’s Disease
23 Sep 2021 Lion TCR Announces FDA IND Clearance for its LioCyx-M004 for Hepatocellular Carcinoma
22 Sep 2021 bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions
20 Sep 2021 Triumvira Doses First Patient with Novel T Cell Therapy in TACTIC-2 Clinical Trial
18 Sep 2021 TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors
16 Sep 2021 Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia
15 Sep 2021 Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
15 Sep 2021 Legend Biotech Begins Phase 1 Clinical Trial in the US to Evaluate Investigational Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma
15 Sep 2021 Neurogene Announces FDA Clearance of IND for NGN-101 Gene Therapy to Treat CLN5 Batten Disease
15 Sep 2021 T-Cure Bioscience Announces U.S. FDA Clearance of Investigator-Initiated Clinical Trial for KK-LC-1 TCR-T Against Multiple Solid Tumors
15 Sep 2021 GammaDelta Therapeutics Initiates First-in-Human Phase 1 Trial of GDX012 for the Treatment of Acute Myeloid Leukaemia
15 Sep 2021 Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma
15 Sep 2021 Excision Receives FDA Clearance of IND for Phase 1/2 Trial of EBT-101 CRISPR-Based Therapeutic for Treatment of HIV
15 Sep 2021 Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial
11 Sep 2021 Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a SELECT-HD Clinical Trial of WVE-003 in Huntington’s Disease
08 Sep 2021 Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinson’s Disease
08 Sep 2021 Ixaka announces positive interim Phase 3 clinical trial data for its lead cell therapy candidate REX-001
07 Sep 2021 TriSalus Life Sciences Announces First Patient Enrolled in PERIO-01 Clinical Trial to Evaluate Delivery of SD-101 via Pressure-Enabled Drug Delivery in Uveal Melanoma Liver Metastases
07 Sep 2021 Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
06 Sep 2021 U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings
06 Sep 2021 JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in China
06 Sep 2021 Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit
03 Sep 2021 Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance
02 Sep 2021 Innovative Cellular Therapeutics Receives FDA Clearance of IND Application to Initiate a Phase 1 Clinical Trial for GCC19CART, a CoupledCAR® Platform Product Candidate for Relapsed or Refractory Metastatic Colorectal Cancer

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up